(Daily News - 03-13-2013)
FDA signaled to pharmacy compounders that it may start flexing its enforcement muscle against those that compound drugs for non-identified patients by warning a South Carolina facility that product it distributed without valid patient prescriptions will be treated as drugs subject to current good manufacturing practices.